How to Get Mounjaro in New Hampshire

What Is Mounjaro and Why Is It Prescribed in New Hampshire?

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that Eli Lilly developed for type 2 diabetes management, with growing off-label use for weight management. The drug works by activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing stronger glycemic control and greater weight reduction than single-receptor GLP-1 drugs like semaglutide.

In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.37% from baseline versus 1.86% with semaglutide 1 mg at 40 weeks, while also producing 12.4 kg mean weight loss compared to 6.2 kg with semaglutide 1. These results made tirzepatide the first dual-incretin therapy to demonstrate superiority over an established GLP-1 agonist in a head-to-head comparison. The FDA approved Mounjaro for type 2 diabetes in May 2022 2.

New Hampshire clinicians prescribe Mounjaro through two primary channels: in-office visits with endocrinologists, internists, or obesity medicine specialists, and telehealth consultations with platforms licensed in the state. Both routes require a clinical evaluation, baseline lab work, and (for insured patients) prior authorization before dispensing.

Telehealth Options for Mounjaro in New Hampshire

New Hampshire allows licensed telehealth providers to prescribe Mounjaro without requiring an initial in-person visit, provided the prescriber holds an active NH medical license. This means residents in rural counties like Coos or Grafton have the same prescription access as those near Dartmouth-Hitchcock Medical Center or Concord Hospital.

A telehealth visit for Mounjaro typically follows this sequence. The provider reviews your medical history, current medications, BMI, and comorbidities. They order baseline labs (discussed below). If clinically appropriate, they submit the prescription to a pharmacy of your choice and, if needed, initiate the prior authorization process with your insurer.

Several telehealth platforms now operate in New Hampshire with physicians specifically credentialed for GLP-1 and incretin prescribing. When choosing a provider, verify three things: that the prescribing clinician is individually licensed by the New Hampshire Board of Medicine (not just the platform), that the platform coordinates prior authorization on your behalf, and that they offer ongoing dose-titration management rather than a one-time prescription. The American Telemedicine Association's 2023 practice guidelines recommend that telehealth weight-management programs include at minimum quarterly follow-up visits and annual lab reassessment 3.

Who Can Prescribe Mounjaro in NH: MD, NP, and PA Authority

New Hampshire grants prescriptive authority to physicians (MDs and DOs), nurse practitioners (APRNs), and physician assistants (PAs), all of whom may prescribe Mounjaro. APRNs in New Hampshire have had full practice authority since 2016, meaning they can prescribe independently without a collaborative agreement with a physician.

PAs in New Hampshire prescribe under a collaborative practice agreement but retain broad latitude for medication selection, including Schedule III through V controlled substances and non-controlled injectables like tirzepatide. For practical purposes, any of these provider types can evaluate you, order labs, write the Mounjaro prescription, and manage your prior authorization.

If your primary care provider is unfamiliar with tirzepatide dosing, the Mounjaro prescribing information specifies a dose-escalation schedule: 2.5 mg weekly for 4 weeks, increasing to 5 mg weekly, with further titration in 2.5 mg increments every 4 weeks up to a maximum of 15 mg weekly [2]. Dose adjustments are guided by glycemic response and tolerability.

Lab Work Required Before Starting Mounjaro in New Hampshire

Most prescribers in New Hampshire require baseline laboratory testing before initiating tirzepatide. There is no state-specific lab mandate, but clinical best practice and insurer requirements align closely.

Standard pre-treatment labs include HbA1c (to confirm diabetic or prediabetic status for on-label use), a comprehensive metabolic panel (CMP) to assess kidney and liver function, a lipid panel, and thyroid-stimulating hormone (TSH). The TSH test matters because tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though human risk remains unconfirmed 2.

Some insurers also require documentation of a BMI measurement (at or above 30 kg/m², or at or above 27 kg/m² with at least one weight-related comorbidity) and evidence that dietary and exercise interventions have been attempted. The Endocrine Society's 2024 clinical practice guideline recommends that clinicians obtain a fasting glucose, HbA1c, and lipid panel before prescribing any incretin-based therapy for weight management 4.

Quest Diagnostics, Labcorp, and hospital-affiliated labs throughout New Hampshire can process these panels. Telehealth patients can complete lab work at any draw site. Results are typically available within 24 to 48 hours.

Prior Authorization for Mounjaro in New Hampshire

Most commercial insurers covering New Hampshire require prior authorization (PA) before they will pay for Mounjaro. The process involves your prescriber submitting clinical documentation to the insurer proving medical necessity.

Here is what PA submissions typically require: a confirmed type 2 diabetes diagnosis (ICD-10 code E11.65 or related), recent HbA1c values, documentation of failure or intolerance of at least one first-line agent (usually metformin), current BMI, and a list of concomitant medications. Some plans also request proof that a GLP-1 monotherapy (such as semaglutide or liraglutide) was tried and proved inadequate before approving the dual-incretin Mounjaro.

PA turnaround varies. Anthem Blue Cross Blue Shield and Cigna plans operating in NH typically respond within 48 to 72 hours for standard requests. Urgent requests may receive a decision within 24 hours. If denied, you have the right to appeal; New Hampshire RSA 420-J:5 requires insurers to provide an external review process for coverage denials 5.

A 2023 analysis in JAMA Network Open found that prior authorization delays GLP-1 therapy initiation by a median of 17 days, with 24% of initial requests denied before appeal 6. Working with a provider who handles PA routinely can reduce this timeline substantially.

New Hampshire Medicaid and Mounjaro Coverage

New Hampshire Medicaid does not cover Mounjaro for weight loss. Coverage for the type 2 diabetes indication is limited and subject to strict formulary placement. The state's Medicaid managed care organizations (MCOs), including Granite State Health Plan (now part of Molina Healthcare) and AmeriHealth Caritas New Hampshire, maintain preferred drug lists that may include other GLP-1 agonists before tirzepatide.

If you have Medicaid and your prescriber believes tirzepatide is medically necessary, a formulary exception request can be submitted. Success rates for these exceptions remain low for off-label weight-loss indications. A study published in Diabetes Care reported that Medicaid formulary restrictions reduced GLP-1 agonist utilization by 38% compared to commercially insured populations 7.

For Medicaid patients who cannot obtain coverage, two alternatives exist: Eli Lilly's Mounjaro Savings Card (available only to commercially insured patients, not Medicaid or Medicare beneficiaries) and compounded tirzepatide through 503A pharmacies, discussed below.

Pharmacy Access and 503A Compounding in New Hampshire

New Hampshire residents can fill brand-name Mounjaro prescriptions at any retail pharmacy. CVS, Walgreens, and Rite Aid locations across the state stock the medication, though supply constraints have intermittently affected availability since 2023. The FDA has periodically listed tirzepatide on its drug shortage database 8.

503A compounding pharmacies licensed in New Hampshire may also prepare tirzepatide formulations when the brand-name product is on the FDA shortage list or otherwise unavailable. These pharmacies compound patient-specific prescriptions under the supervision of a licensed pharmacist. New Hampshire's Board of Pharmacy regulates 503A facilities under RSA 318, and compounded medications must be dispensed pursuant to a valid individual prescription.

Compounded tirzepatide typically costs less than brand-name Mounjaro. Cash prices for compounded formulations commonly range from $250 to $500 per month, compared to $1,000+ for the brand product without insurance. The tradeoff is that compounded products do not undergo the same FDA approval process as manufactured drugs, and potency, sterility, and consistency depend on the compounding pharmacy's quality controls.

Before using a compounded product, verify that the pharmacy holds current licensure with the New Hampshire Board of Pharmacy, maintains PCAB (Pharmacy Compounding Accreditation Board) accreditation or equivalent, and performs third-party potency and sterility testing on each batch. The FDA's 2023 guidance on compounded GLP-1 agonists emphasizes that patients should be informed these products are not FDA-approved 9.

Cost and Savings Strategies for Mounjaro in New Hampshire

Brand-name Mounjaro carries a list price of approximately $1,023 per month for a 4-pen, 4-week supply. Out-of-pocket costs vary widely based on insurance coverage, plan tier, and copay assistance.

Several strategies can reduce what you pay. Eli Lilly's Mounjaro Savings Card lowers the copay to as little as $25 per month for eligible commercially insured patients. This card cannot be used with government insurance programs (Medicare, Medicaid, Tricare). Patients receiving the medication through a telehealth platform should confirm that the platform's pharmacy accepts the savings card.

For uninsured or self-pay patients, manufacturer patient assistance programs and compounded tirzepatide are the primary cost-reduction options. Some NH-based independent pharmacies also offer competitive cash pricing when purchased outside insurance. The IQVIA Institute reported that manufacturer copay assistance covered 52% of branded GLP-1 prescriptions in 2024, reducing average out-of-pocket costs from $312 to $47 per fill 10.

Timeline: How Long Until You Receive Mounjaro in New Hampshire

The total time from your first appointment to injection depends on several variables. Here is a realistic timeline for most patients.

Week 1: initial consultation (telehealth or in-person) plus lab orders. Labs return within 1 to 2 business days. Week 1 to 2: prescriber reviews labs, submits the prescription, and initiates prior authorization if required. PA decisions take 2 to 5 business days on average. Week 2 to 3: once approved, the pharmacy dispenses the medication. Retail pharmacies may fill same-day if the drug is in stock. Specialty and mail-order pharmacies ship within 1 to 3 business days.

Total estimated timeline: 7 to 21 days from first appointment to first injection. Patients who self-pay and skip the PA process can often receive the medication within 3 to 7 days.

If your pharmacy reports a stock-out, ask your prescriber to send the prescription to a different location or a specialty pharmacy. The Mounjaro supply situation has improved through 2025 and 2026, but periodic spot shortages still occur.

Transferring a Mounjaro Prescription to New Hampshire

If you are moving to New Hampshire or splitting time between states, your existing Mounjaro prescription can be transferred. New Hampshire follows standard prescription transfer rules under RSA 318:47-b. Your current pharmacy can transfer the prescription electronically or by phone to any NH-licensed pharmacy.

For patients moving from a state where they saw a prescriber in person, the new NH-based provider (or telehealth platform licensed in NH) will need to establish care and may require updated labs before continuing the prescription. This typically adds 1 to 2 weeks to the refill timeline. No prescription gap should occur if you plan the transfer before your current supply runs out.

Side Effects and Monitoring After Starting Mounjaro

The most common adverse effects in SURPASS-2 were gastrointestinal: nausea (12% to 23% depending on dose), diarrhea (12% to 17%), and decreased appetite 1. These effects are dose-dependent and tend to diminish after 4 to 8 weeks at a stable dose. Slow titration (remaining at each dose level for a full 4 weeks before escalating) is the most effective mitigation.

Serious but rare adverse events include pancreatitis (reported in <0.2% of trial participants), gallbladder events, and hypoglycemia when used alongside sulfonylureas or insulin. The prescribing label also notes the thyroid C-cell tumor boxed warning, making tirzepatide contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 2.

New Hampshire prescribers should schedule follow-up labs (HbA1c, metabolic panel) at 3 months and 6 months after initiation, then annually. Weight, blood pressure, and gastrointestinal symptom review should occur at each dose adjustment visit.

The SURPASS-2 data showed that patients who completed the full 40-week titration protocol achieved the greatest HbA1c and weight reduction, reinforcing the value of consistent clinical follow-up rather than self-directed dose changes 1. Patients in New Hampshire who start on a 2.5 mg dose and titrate to 15 mg over 20 weeks should expect measurable HbA1c improvement by week 12 and peak weight loss by weeks 36 to 40.